- Home
- AEC vs LUNG Comparison
AEC vs LUNG Comparison
Compare AEC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEC | LUNG |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 72.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AEC | LUNG |
|---|---|---|
| Price | $6.74 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 59.1K | ★ 374.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $4.42 | $1.31 |
| 52 Week High | $12.49 | $8.10 |
Technical Indicators
Market Signals| Indicator | AEC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 39.58 |
| Support Level | $5.95 | $1.34 |
| Resistance Level | $7.36 | $1.93 |
| Average True Range (ATR) | 0.55 | 0.11 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 47.83 | 24.14 |
Price Performance
Historical ComparisonAbout AEC Anfield Energy Inc.
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One. The company's geographical segments are Canada and the United States.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.